Sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate | 248282-07-7

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate
• CAS: 248282-07-7
• 化学式: C19H17ClN2NaO3
• 分子量: 379.8
• InChiKey: AHIFNCNCUYJCOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate 、 Calcium acetate hydrate, 99.99% trace metals basis 在 水 作用下， 以 乙醇 、 水 为溶剂， 反应 0.5h， 生成 n-Ethyl-n-phenyl-5-chloro-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide calcium salt
  参考文献：
  名称：

  Crystalline salts of quinoline compounds and methods for preparing them

  摘要：

  一种稳定的固体药物组成物，基本上包括公式（II）的晶体盐的有效量，以及维持pH值在8以上的碱性反应组分，或者是带有二价金属阳离子的盐；以及至少一种药用辅料；所述公式（II）的盐在室温下储存至少3年期间基本上是稳定的。一种稳定公式（II）的盐的方法。公式（II）的晶体盐和制备该盐的方法。

  公开号：

  US08314124B2

文献信息

• HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Dixit Girish

  公开号：US20120009226A1

  公开（公告）日：2012-01-12

  Provided herein is an impurity of laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide (deschloro laquinimod impurity), and process for preparation and isolation thereof. Provided further herein is a highly pure laquinimod or a pharmaceutically acceptable salt thereof substantially free of deschloro laquinimod impurity, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure laquinimod or a pharmaceutically acceptable salt thereof substantially free of deschloro laquinimod impurity.

  本文提供了拉奎尼莫德的杂质，即N-乙基-N-苯基-1,2-二氢-4-羟基-1-甲基-2-氧基喹啉-3-甲酰胺（去氯拉奎尼莫德杂质）的过程及其制备和分离。此外，本文还提供了高纯度的拉奎尼莫德或其药用可接受盐，基本上不含去氯拉奎尼莫德杂质，以及其制备过程和包含高纯度的拉奎尼莫德或其药用可接受盐的药物组合物。
• New compositions containing quinoline compounds
  申请人：Jansson Karl

  公开号：US20050192315A1

  公开（公告）日：2005-09-01

  A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

  一种稳定的固体制药组合物，基本上包含有效量的公式（II）的盐，以及维持pH在8以上的碱性反应组分，或者含有二价金属阳离子的盐；以及至少一种制药辅料；所述的公式（II）的盐在室温下储存至少3年期间基本稳定。一种稳定公式（II）的盐的方法。公式（II）的结晶盐及其制备方法。
• NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT
  申请人：Dixit Girish

  公开号：US20110171270A1

  公开（公告）日：2011-07-14

  Provided herein is a novel crystalline form of laquinimod, process for the preparation, pharmaceutical compositions, and method of treating thereof. Provided also herein are novel amorphous and polymorphic forms of laquinimod sodium, process for the preparation, pharmaceutical compositions, and method of treating thereof.

  本文提供了一种新型晶体形式的拉奎尼莫德，其制备方法、制药组合物和治疗方法。本文还提供了拉奎尼莫德钠的新型非晶态和多晶态形式，其制备方法、制药组合物和治疗方法。
• CRYSTALLINE SALTS OF QUINOLINE COMPOUNDS AND METHODS FOR PREPARING THEM
  申请人：Jansson Karl

  公开号：US20090232889A1

  公开（公告）日：2009-09-17

  A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

  一种稳定的固体药物组合物，基本上包括公式（II）的晶体盐的有效量，以及维持pH值优选高于8的碱性反应组分或具有二价金属阳离子的盐；以及至少一种药物辅料；所述公式（II）的盐在室温下储存至少3年期间基本稳定。一种稳定公式（II）盐的方法。公式（II）的晶体盐及其制备方法。
• Compositions containing quinoline compounds
  申请人：Active Biotech AB

  公开号：US07589208B2

  公开（公告）日：2009-09-15

  A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

  一种稳定的固体制药组合物，基本上由公式（II）的盐的有效量和维持pH值优选在8以上的碱性反应成分或含有二价金属阳离子的盐，以及至少一种制药辅料组成；所述公式（II）的盐在常温下储存期间基本上稳定至少3年。一种稳定公式（II）的盐的过程。公式（II）的结晶盐及其制备过程。